BeckerKL, NylenES, WhiteJC, MullerB, SniderRHJr.2004. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab, 89:1512–1525.
2.
LinscheidP, SeboekD, NylenES, LangerI, SchlatterM, BeckerKL, KellerU, MullerB. 2003. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology, 144:5578–5584.
3.
MullerB, WhiteJC, NylenES, SniderRH, BeckerKL, HabenerJF. 2001. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab, 86:396–404.
4.
BrunkhorstFM, HeinzU, ForyckiZF. 1998. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med, 24:888–889.
5.
NovotnyA, EmmanuelK, MatevossianE, KrinerM, UlmK, BartelsH, HolzmannB, WeighardtH, SiewertJR. 2007. Use of procalcitonin for early prediction of lethal outcome of postoperative sepsis. Am J Surg, 194:35–39.
6.
ReithHB, MittelkotterU, DebusES, KussnerC, ThiedeA. 1998. Procalcitonin in early detection of postoperative complications. Dig Surg, 15:260–265.
BergholmU, AdamiHO, Telenius-BergM, JohanssonH, WilanderE. 1990. Incidence of sporadic and familial medullary thyroid carcinoma in Sweden 1959 through 1981. A nationwide study in 126 patients. Swedish MCT Study Group. Acta Oncol, 29:9–15.
9.
GuilloteauD, PerdrisotR, CalmettesC, BaulieuJL, LecomteP, KaphanG, MilhaudG, BesnardJC, JalletP, BigorgneJC. 1990. Diagnosis of medullary carcinoma of the thyroid (MCT) by calcitonin assay using monoclonal antibodies: criteria for the pentagastrin stimulation test in hereditary MCT. J Clin Endocrinol Metab, 71:1064–1067.
10.
BihanH, BeckerKL, SniderRH, NylenE, VittazL, LauretC, ModiglianiE, MorettiJL, CohenR. 2003. Calcitonin precursor levels in human medullary thyroid carcinoma. Thyroid, 13:819–822.
11.
BolkoP, Manuszewska-JopekE, MichalekK, WaskoR, JaskulaM, SowinskiJ. 2003. Efficacy of procalcitonin measurement in patients after total thyroidectomy due to medullary thyroid carcinoma. Arch Immunol Ther Exp (Warsz), 51:415–419.
12.
IttnerL, BornW, RauB, SteinbachG, FischerJA. 2002. Circulating procalcitonin and cleavage products in septicaemia compared with medullary thyroid carcinoma. Eur J Endocrinol, 147:727–731.
13.
AssicotM, GendrelD, CarsinH, RaymondJ, GuilbaudJ, BohuonC. 1993. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet, 341:515–518.
14.
MeisnerM, TschaikowskyK, PalmaersT, SchmidtJ. 1999. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care, 3:45–50.
15.
DandonaP, NixD, WilsonMF, AljadaA, LoveJ, AssicotM, BohuonC. 1994. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab, 79:1605–1608.
16.
MeisnerM, LohsT, HuettemannE, SchmidtJ, HuellerM, ReinhartK. 2001. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol, 18:79–87.
17.
KuseER, LangefeldI, JaegerK, KulpmannWR. 2000. Procalcitonin-a new diagnostic tool in complications following liver transplantation. Intensive Care Med, 26,Suppl 2:S187–192.
18.
MeisnerM, TschaikowskyK, HutzlerA, SchickC, SchuttlerJ. 1998. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med, 24:680–684.
19.
MachensA, GimmO, UkkatJ, HinzeR, SchneyerU, DralleH. 2000. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer, 88:1909–1915.
